ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Priothera has raised about $35 million in series A financing to develop drugs for acute myeloid leukemia (AML). The Dublin-based company will use the funds to test mocravimod in a clinical trial of people with AML who are also receiving allogeneic stem cell transplants. Mocravimod is intended to reduce the risk of graft versus host disease and boost the efficacy of the stem cell transplant by targeting sphingosine-1-phosphate receptors. Priothera acquired mocravimod from Kyorin Pharmaceutical, which had licensed it to Novartis.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X